Steven Leonard Chapman, the chief executive officer and president of diagnostics firm Natera Inc. (NASDAQ:NTRA), sold common stock totaling approximately $1.56 million on November 2, 2026, according to a recent filing with the Securities and Exchange Commission. The transactions were executed at prices ranging between $387.90 and $415.64 per share. At the time of reporting, Natera stock was trading at $391.03, reflecting a 10% decline over the previous week despite a 96% gain over the last year.

The sale consisted of two distinct components governed by Rule 10b5-1(c) of the Exchange Act. First, 935 shares were sold to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs), pursuant to a Stock Unit Agreement granted on January 31, 2025. Second, an additional 2,866 shares were liquidated under a pre-arranged trading plan initially adopted by Chapman on December 11, 2023, and subsequently amended on December 2, 2024, and March 5, 2026. Following these transactions, Chapman directly beneficially owns 87,431 shares of Natera common stock.

While the insider sale occurred against a backdrop where some analysis suggests limited upside at current valuation levels, recent corporate performance has drawn positive attention from Wall Street. Natera recently reported second-quarter revenue of approximately $753 million, significantly surpassing the consensus forecast of $661.26 million by nearly 14%. This beat was driven by record test volumes, improved margins, and regulatory successes, prompting the company to raise its full-year revenue guidance.

Analysts have responded with increased price targets and bullish sentiment. BTIG raised its target to $430, anticipating a 7% revenue beat in the third quarter and highlighting growth in Signatera units. RBC Capital increased its target to $460, citing Natera's dominant position in the minimal residual disease testing market. Roth/MKM initiated coverage with a buy rating and a $475 price target, pointing to the company's oncology diagnostics pipeline, while Rothschild Redburn set a target of $385, emphasizing leadership in minimal residual disease testing.

Sources: Investing.com News.